PubMed · 1990 · 17 citations · 9 references
MedicineNephrologySurgeryKidney TransplantationTransplant SurgeryImmunosuppression In Kidney TransplantationRenal DiseaseRenal PhysiologyTransplant RejectionTransplantation
FK 506 was tested in unrelated baboons submitted to renal transplantation and bilateral native nephrectomy. Untreated baboons died after 9.2 ± 4.0 SD days. When FK 506 was given orally for 90 days, survival with the optimum dose was 74.6 ± 28.9 days; this allowed maximum credit for each individual animal of 90 days. A 3-day course of intramuscular FK 506 started on postoperative day 4 allowed 1- to 2-month survival. Delayed rejection in these baboons as well as in those treated daily for 90 days with FK could sometimes be reversed temporarily with a second 3-day course. The doses required for a good therapeutic effect were 10 times greater in baboons than in dogs, a finding that may reflect a species difference of lymphocyte sensitivity to this drug. FK appeared to be relatively nontoxic in subhuman primates, and it remains a promising drug for clinical trial. © 1989.
9
Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.
S Sawada, Gen Suzuki, Yoshiko Kawase et al. · The Journal of Immunology · 1987 · 417 citations · Full text
A. Zeevi, R Duquesnoy, G Eiras et al. · PubMed · 1987 · 92 citations · Full text
Orthotopic liver transplantation in dogs receiving FK-506.
Satoru Todo, Luis G. Podestá, Paulo Chapchap et al. · PubMed · 1987 · 65 citations · Full text
Toxicology of FK-506 in the Lewis rat.
Michael A. Nalesnik, S Todo, Noriko Murase et al. · PubMed · 1987 · 63 citations · Full text
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.
S Todo, Demetris Aj, Yutaka Ueda et al. · PubMed · 1987 · 55 citations · Full text
Medicine, Nephrology, Surgery +12